Precise and Efficient Non-viral CRISPR Gene Editing Solutions for T Cell Engineering

With the 5^th approval on CAR-T therapy (Abecma) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment. The delivery of a specifically designed chimeric antigen receptor (CAR) or T cell receptor (TCR) encoding component can be done by viral vectors, but this approach has limitations like random insertion and complicated vector manufacture process. Nowadays, with the power of CRISPR gene editing, precise and efficient T cell engineering can be carried out in a non-viral, plasmid-free manner. GenScript has developed several tools and reagents to overcome these challenges. We will show data on how dedicated reagents are crucial to achieve high editing efficiency and cell viability for precise CAR/TCR KI in T cells. Meanwhile, with the upgraded capability and recent advances in non-viral delivery of CRISPR components, it will become increasingly possible to engineer T cells into therapeutics via non-viral regulation-compliant manufacture process.

Speaker-related Webinars

Unleashing the Power of Non-Viral Gene Editing: Transforming Cell Therapy Development

With the fast progress and deeper understanding of CAR-T cell therapy, finding a better solution other than lentivirus transduction is more requested, to overcome the functional limitation on random insertion, uncontrolled copy number of CAR insertion and

Learn More

Precise and Efficient Non-viral CRISPR Gene Editing Solutions for T Cell Engineering

With the 5^th approval on CAR-T therapy (Abecma) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment.

Learn More